Roche has signed a definitive agreement to acquire 89bio, for a total equity value of approximately US$3.5 B. Through the takeover, Roche will gain access to 89bio’s lead asset, pegozafermin, a potential best-in-disease treatment for patients suffering from moderate to severe liver fibrosis and cirrhotic metabolic dysfunction-associated steatohepatitis (MASH). The acquisition supports Roche’s strategic focus on cardiovascular, renal, and metabolic (CVRM) diseases, particularly for patients dealing with obesity and related conditions like MASH.